Am J Transplant, Volume 22, Suppl 3 Archives - Page 141 of 190 - ATC Abstracts

2022 American Transplant Congress
Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality
S. Weeks, T. Ishaque, A. Massie, D. Segev, E. King
Johns Hopkins, Baltimore, MD
*Purpose: Liver transplant candidates with hepatocellular carcinoma (HCC) risk tumor progression that may disqualify them from transplant eligibility while awaiting HCC exception points on the…
2022 American Transplant Congress
Excellent Long-Term Outcome of ABO-Incompatible Living Kidney Transplantation by Reduced-Session of Plasmapheresis of Desensitization Protocol
Y. Ishiyama¹, K. Tanabe², T. Kanzawa², K. Unagami², H. Ishida², T. Takagi²
¹Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan, ²Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Plasmapheresis (PE) is applied to ABO-incompatible living kidney transplantation (ABOi-LKT) in order to remove ABO blood type antibody to obtain the appropriate target levels.…
2022 American Transplant Congress
Growing Use of Perfusion for Heart, Liver, and Lung and Early Outcomes
R. R. Goff¹, K. Gauntt¹, W. Cherikh¹, E. D. Lease², D. Klassen¹
¹United Network for Organ Sharing, Richmond, VA, ²University of Washington, Seattle, WA
*Purpose: In 2015 the OPTN began collecting data on perfusion for heart, liver, and lung deceased donors (DD) on the DD registration form. Since 2015,…
2022 American Transplant Congress
HDAC Inhibitors Suppress Endothelial Inflammation but Alter Identity
N. M. Valenzuela
Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
*Purpose: Histone modifications such as acetylation control gene expression. Histone deacetylases (HDACs) have been proposed as an attractive therapeutic approach to counteract detrimental gene expression,…
2022 American Transplant Congress
Sars-cov-2 Antibodies Transitions After Vaccination In Solid Organ Transplant Recipients: Multicenter Study In Japan
K. Unagami¹, M. Yoshikawa², Y. Natori³, K. Omoto¹, H. Ishida¹, H. Date⁴, R. Imamura⁵, T. Ito⁴, K. Miyaji⁶, S. Takahara⁷, K. Yuzawa⁸, O. Satoko⁹, Y. Hirota¹⁰, H. Egawa¹
¹Tokyo Women's Medical University, Tokyo, Japan, ²Kyoto Prefectural University of Medicine, Kyoto, Japan, ³University of Miami, Pinecrest, FL, ⁴Kyoto University, Kyoto, Japan, ⁵Dept. of Urology, Osaka Univ. Graduate School of Medicine, Suita, Japan, ⁶Renal Transplantation, Takatsuki General Hospital, Takatsuki, Japan, ⁷Kansai Medical Hospital, Toyonaka, Japan, ⁸Tranplantation Surgery, National Hospital Organization Mito Medical Center, Mito, Japan, ⁹Public Health, Osaka City University Graduate School of Medicine and Research Center for Infectious, Osaka City University Graduate School of Medicine, Osaka, Japan, ¹⁰Clinical Epidemiology Research Center, Miyama, Japan
*Purpose: For purpose of SARS-CoV-2 infection control, vaccination was started in worldwide, however, low reactivity of antibody production after vaccination is a concern for solid…
2022 American Transplant Congress
Pancreas Transplants Outcomes in Diabetes Mellitus Type 1 and Type 2 in the 21^st Century: Are They Two Different Populations?
M. Merzkani¹, H. Murad², M. Wang¹, V. Hu¹, M. Ji³, Y. Al-Hosni¹, O. Alzahabi¹, M. Zayed¹, J. Wellen⁴, K. Lentine⁵, S. Chang⁶, T. Alhamad⁷
¹Washington University, St Louis, MO, ²Washington University in St Louis, Chesterfield, MO, ³Washington University in St. Louis School of Medicine, Saint Louis, MO, ⁴Washington University School of Medicine, Saint Louis, MO, ⁵SLU, St Louis, MO, ⁶Surgery, Washington University School of Medicine, Saint Louis, MO, ⁷Washington University School of Medicine at St. Louis, Saint Louis, MO
*Purpose: Pancreas alone transplant (PT) has been associated with decreased progression and regression of microvascular and macrovascular complications. In this current era of standardized immunosuppression,…
2022 American Transplant Congress
Estimating the Effect of Increased Donor Heart Ischemic Time on Post-Transplant Survival Using Instrumental Variables
G. Ran¹, K. Lazenby¹, N. Narang², W. F. Parker³
¹Pritzker School of Medicine, University of Chicago, Chicago, IL, ²Department of Medicine, University of Illinois-Chicago, Chicago, IL, ³Department of Medicine, University of Chicago, Chicago, IL
*Purpose: Isolate the impact of organ ischemic time on post-transplant survival using the recent change in heart allocation policy as a natural experiment.*Methods: We examined…
2022 American Transplant Congress
Prospective Analysis of the Impact of Impella 5.5 Devices on HLA Antibody Development in Transplant Recipients
K. Castro, J. Van Zyl, R. Doss, S. McKean, J. Russelia, A. Alam, M. Askar, S. Hall
Heart and lung Transplant Research, Baylor University Medical Center, Dallas, TX
*Purpose: Little is known about the development of Human Leukocyte Antigen antibodies with the use of the new Impella 5.5 temporary mechanical circulatory assist device.*Methods:…
2022 American Transplant Congress
The Paradox of Lifestyle – Related Liver Disease: ASH and NASH
N. Kemmer¹, J. Buggs²
¹Transplant Hepatology, Tampa General Hospital, Tampa, FL, ²Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: In the last decade, the burden of lifestyle-related chronic disease has been on the rise and is considered a growing serious public health concern.…
2022 American Transplant Congress
Circulating Donor-Derived Cell-Free DNA: A Novel Non-Invasive Biomarker for Immune Surveillance in Vascularized Composite Allotransplantation
W. J. Rifkin¹, J. Trilles¹, P. S. Rabbani¹, O. C. Onuh¹, B. E. Gelb², D. J. Ceradini¹, E. D. Rodriguez¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, ²Transplant Institute, NYU Langone Health, New York, NY
*Purpose: The purpose of this study is to evaluate whether circulating donor-derived cell-free DNA (dd-cfDNA) could be used as a noninvasive biomarker to detect rejection…